Metis TechBio and Eli Lilly Strike Drug-Delivery Deal Worth Up to $1.1 Billion
Metis TechBio said it entered a collaboration agreement with Eli Lilly to research and develop tissue-specific drug-delivery technologies, worth up to $1.1 billion.
Hong Kong-listed Metis TechBio HKEX:7666 said on Monday it had entered into a collaboration agreement with Eli Lilly NYSE:LLY, valued at up to $1.1 billion, to research and develop tissue-specific drug-delivery technologies. Metis TechBio will use its proprietary AI-driven drug-delivery platform to…